These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 4091866)

  • 1. N-Alkyl barbiturates. A series of compounds for the study of metabolic structure-activity relationships.
    Treston AM; Hooper WD
    Arzneimittelforschung; 1985; 35(11):1627-9. PubMed ID: 4091866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biotransformation of N-methylcyclobarbital in vivo in rabbit and rat.
    Miyano K; Shimodouzono Y; Toki S
    Xenobiotica; 1985 May; 15(5):381-9. PubMed ID: 2863899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminomethyl derivatives of 1-cyclohexyl-5-alkyl- and 1-cyclohexyl-5,5-dialkylbarbituric acids as potential antiinflammatory agents.
    Sladowska H
    Farmaco Sci; 1979 Nov; 34(11):979-86. PubMed ID: 45267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver.
    Chou CH; Evans AM; Fornasini G; Rowland M
    Drug Metab Dispos; 1993; 21(5):933-8. PubMed ID: 7902258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and disposition studies with a [35S]-labelled growth promotor: bis(N1-methyl-N2-methylsulphonyl) guanidinylethyl] disulphide.
    Facchini V; Jones M; Smith GE
    Drug Metabol Drug Interact; 1989; 7(1):17-28. PubMed ID: 2633893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR in drug metabolism and disposition. An application to the affinity for cytochrome P-450 and hepatic clearance of barbiturates.
    Testa B
    Pharm Acta Helv; 1978; 53(5):143-6. PubMed ID: 724727
    [No Abstract]   [Full Text] [Related]  

  • 7. [Optically active barbiturates. Synthesis, configuration and pharmacological effects (author's transl)].
    Knabe J; Rummel W; Büch HP; Franz N
    Arzneimittelforschung; 1978; 28(7):1048-56. PubMed ID: 385006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bucolome N-glucuronide: purification and identification of a major metabolite of bucolome in rat bile.
    Mohri K; Uesugi T; Kamisaka K
    Xenobiotica; 1985 Jul; 15(7):615-21. PubMed ID: 2864761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism of certain commonly used barbiturates.
    Freudenthal RI; Carroll FI
    Drug Metab Rev; 1973; 2(2):265-78. PubMed ID: 4604760
    [No Abstract]   [Full Text] [Related]  

  • 10. Synthesis and opioid activity of [D-Pro10]dynorphin A-(1-11) analogues with N-terminal alkyl substitution.
    Choi H; Murray TF; DeLander GE; Schmidt WK; Aldrich JV
    J Med Chem; 1997 Aug; 40(17):2733-9. PubMed ID: 9276018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On-column gas chromatographic synthesis of 1,3-dialkyl (c = 1-10), benzyl, and cyclohexyl barbiturate derivatives.
    Budd RD
    Clin Toxicol; 1980 Apr; 16(2):189-99. PubMed ID: 7398209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of some homologous series of barbiturates in the intact rat and in the isolated perfused rat liver.
    Yih TD; van Rossum JM
    J Pharmacol Exp Ther; 1977 Oct; 203(1):184-92. PubMed ID: 909052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of distribution and adipose tissue storage as a function of lipophilicity and chemical structure. I. Barbiturates.
    Steiner SH; Moor MJ; Bickel MH
    Drug Metab Dispos; 1991; 19(1):8-14. PubMed ID: 1673426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K5 values of some homologous series of barbiturates and the relationship with the lipophilicity and metabolic clearance.
    Yih TD; van Rossum JM
    Biochem Pharmacol; 1977 Nov; 26(22):2117-20. PubMed ID: 588293
    [No Abstract]   [Full Text] [Related]  

  • 15. [Barbituric acid derivatives. 38. Enantio-specific synthesis for enantiomers of barbiturates with a basic side chain on nitrogen].
    Knabe J; Lampen P
    Arch Pharm (Weinheim); 1987 Aug; 320(8):756-61. PubMed ID: 3675167
    [No Abstract]   [Full Text] [Related]  

  • 16. The metabolic fate of 5-(bicyclo-3,2,1,-oct-2-en-2-yl)-5-ethyl barbituric acid, (Reposal).
    Nielsen P; Tarding F
    Acta Pharmacol Toxicol (Copenh); 1968; 26(6):521-30. PubMed ID: 5756387
    [No Abstract]   [Full Text] [Related]  

  • 17. Search for CNS active agents: synthesis of N,N'-bis-[potassium-alkyl/aryl carboxylate]-5-arylidene barbituric acids.
    Tiwari SS; Agarwal R; Satsangi RK
    Pol J Pharmacol Pharm; 1981; 33(1):115-20. PubMed ID: 7255277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of in vivo tissue distribution from in vitro data. 3. Correlation between in vitro and in vivo tissue distribution of a homologous series of nine 5-n-alkyl-5-ethyl barbituric acids.
    Ballard P; Leahy DE; Rowland M
    Pharm Res; 2003 Jun; 20(6):864-72. PubMed ID: 12817889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-pharmacokinetic relationships among the barbiturates in the rat.
    Toon S; Rowland M
    J Pharmacol Exp Ther; 1983 Jun; 225(3):752-63. PubMed ID: 6864531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationships of new 9-N-alkyl derivatives of 9(S)-erythromycylamine.
    Kirst HA; Wind JA; Leeds JP; Willard KE; Debono M; Bonjouklian R; Greene JM; Sullivan KA; Paschal JW; Deeter JB
    J Med Chem; 1990 Nov; 33(11):3086-94. PubMed ID: 2231610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.